REVANCE THERAPEUTICS INC's ticker is RVNC and the CUSIP is 761330109. A total of 160 filers reported holding REVANCE THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 2.13 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,293,797 | -28.2% | 51,118 | -8.6% | 0.08% | -33.1% |
| Q1 2023 | $1,801,312 | +805.9% | 55,924 | +419.2% | 0.13% | +807.1% |
| Q4 2022 | $198,851 | +44.1% | 10,772 | +109.7% | 0.01% | +40.0% |
| Q3 2022 | $138,000 | +6800.0% | 5,136 | +5670.8% | 0.01% | – |
| Q3 2021 | $2,000 | 0.0% | 89 | +7.2% | 0.00% | – |
| Q2 2021 | $2,000 | -96.0% | 83 | -95.9% | 0.00% | -100.0% |
| Q3 2020 | $50,000 | +28.2% | 2,027 | +25.7% | 0.01% | +20.0% |
| Q2 2020 | $39,000 | -15.2% | 1,613 | -48.7% | 0.01% | -83.3% |
| Q1 2020 | $46,000 | +64.3% | 3,147 | +41.9% | 0.03% | +900.0% |
| Q3 2019 | $28,000 | -66.7% | 2,217 | -34.4% | 0.00% | -50.0% |
| Q3 2018 | $84,000 | +2000.0% | 3,381 | +1832.0% | 0.01% | – |
| Q2 2018 | $4,000 | -97.1% | 175 | -95.5% | 0.00% | -100.0% |
| Q4 2017 | $138,000 | -0.7% | 3,861 | -11.6% | 0.01% | -48.0% |
| Q2 2015 | $139,000 | – | 4,367 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 4,405,039 | $118,936,000 | 9.40% |
| Essex Woodlands Management, Inc. | 457,085 | $12,341,000 | 5.10% |
| Evolutionary Tree Capital Management, LLC | 191,868 | $5,180,000 | 4.98% |
| Ghost Tree Capital, LLC | 390,000 | $10,530,000 | 2.96% |
| Antara Capital LP | 4,069,400 | $109,874,000 | 2.90% |
| RICE HALL JAMES & ASSOCIATES, LLC | 896,754 | $24,212,000 | 1.40% |
| Jericho Capital Asset Management L.P. | 714,000 | $19,278,000 | 1.22% |
| Antara Capital LP | 1,600,000 | $43,200,000 | 1.14% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 120,000 | $3,240,000 | 1.04% |
| TANG CAPITAL MANAGEMENT LLC | 287,500 | $7,763,000 | 0.95% |